Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
about
Available and emerging treatments for Parkinson's disease: a reviewMotor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned ratsTime and sex-dependent effects of an adenosine A2A/A1 receptor antagonist on motivation to self-administer cocaine in rats.Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient miceAdenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Wheel running alters patterns of uncontrollable stress-induced cfos mRNA expression in rat dorsal striatum direct and indirect pathways: A possible role for plasticity in adenosine receptorsPast, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptorsTarget identification for CNS diseases by transcriptional profiling.Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseNovel investigational adenosine A2A receptor antagonists for Parkinson's disease.Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice.The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum.SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization.Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.Adenosine A1 receptor blockade mimics caffeine's attenuation of ethanol-induced motor incoordination.Cellular distribution of adenosine A2A receptor mRNA in the primate striatum.Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.Adenosine A2AReceptors and NeuroprotectionElectrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2Areceptors in dopamine D2receptor regulation in the rat dopamine-denervated striatum
P2860
Q24633444-253BC180-8968-4B08-BBC1-1C14D6ECDED7Q28210110-EF3B6259-B776-4FBD-B65D-E699386753FDQ28266492-81E2882F-1AD4-4327-8885-5300A96D2FECQ28593583-0D3DE558-88B3-40E7-8400-B582813E7C28Q30482913-A44A9DF5-F26C-4EC9-930A-4A5C10E25664Q34337032-8CEB1814-99A1-4D20-AC93-9675A0C78058Q35489240-3248053D-58F7-40CD-9750-77E36CAEC3E6Q36882447-F7030ED6-2078-4DE5-94AE-407664C209BBQ37120419-59A6355F-3537-4ACF-8F00-24AC0342B69CQ37175279-BAD34D41-A809-4D7C-891B-6A1BAC147067Q37358676-8A1937BC-8115-4A3A-A8A9-E8C519A55160Q37627259-C0EDEBC4-5825-4C7A-825A-E6CE04B0C40AQ37844573-FBB4DEE3-B0E4-4403-8653-5A7C04F5A9A8Q38092819-3ACC6232-BAAB-4850-ABC5-B82AAF902506Q38169996-3F8EB0A1-912C-4E61-B999-AF653BD0CE23Q38200930-954A4F5A-C4D4-4563-911E-496EB2854118Q43067040-E25FD6DA-4C79-4A18-AC3F-26C91D3C82BAQ43180903-AAE04AC7-A2C6-40E7-B17B-2992C062D83FQ43635686-0F979FA6-387A-4AC6-816E-D280F3B4D17FQ43795840-23EB553A-99ED-4DEC-8581-CDB37BF6384FQ43959920-1537EC31-EF75-4625-8C4A-3198015CEC41Q44175279-6C597D72-0A65-41EC-B1DA-EA76F030045DQ44407165-326CA7B8-567A-4797-9B34-CF8973E29F6CQ44811440-1DF7595A-BD04-4A49-B73C-9E83BC1CDA06Q45166177-FA572591-4D8E-42D1-B00E-F6B85A2401EFQ48403038-6754D31B-E741-46FF-88FC-671397D7710BQ48867898-C7E7B647-DAA1-43DA-BC3D-E92581EF7DE5Q56700736-6821D52A-7321-4638-BD98-BBF4EAD17C02Q57708646-175C6866-BB41-4999-94B5-A92381291DD8
P2860
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@en
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@nl
type
label
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@en
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@nl
prefLabel
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@en
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@nl
P2093
P1476
Adenosine A2A receptor antagon ...... hydroxydopamine-lesioned rats.
@en
P2093
P304
P356
10.1016/S0014-2999(96)00944-2
P407
P577
1997-02-01T00:00:00Z